drugset / Trial / NCT00253747

Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00253747

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to evaluate whether Osmotic-Release Methylphenidate (OROS MPH), relative to placebo, increases the effectiveness of standard smoking treatment (i.e., nicotine patch and individual smoking cessation counseling) in obtaining prolonged abstinence for smokers with Attention Deficit Hyperactivity Disorder (ADHD).

Timeline

Start
2005-11
Primary completion
2008-01
Completion
2008-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Methylphenidate Small molecule 72 mg Oral